Kalaris Therapeutics Q1 2025 Revenue at $4.96M
Ticker: KLRS · Form: 10-Q · Filed: May 14, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, revenue
TL;DR
Kalaris Q1 revenue $4.96M, watch Series B-2 preferred and bridge notes.
AI Summary
Kalaris Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $4.96 million in revenue for the first quarter of 2025. Key financial instruments mentioned include Series B-2 Redeemable Convertible Preferred Stock and Twenty Twenty-Five Bridge Notes.
Why It Matters
This filing provides investors with a quarterly update on Kalaris Therapeutics' financial performance and the status of its convertible preferred stock and bridge notes.
Risk Assessment
Risk Level: medium — The company's financial performance and the nature of its preferred stock and bridge notes suggest a moderate level of risk.
Key Numbers
- $4.96M — Q1 2025 Revenue (Revenue for the first quarter of 2025.)
- 0.201601 — Diluted EPS (Earnings per share for the period.)
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Filer
- $4.96 million (dollar_amount) — Q1 2025 Revenue
- March 31, 2025 (date) — Reporting Period End Date
- klrs:SeriesBTwoRedeemableConvertiblePreferredStockMember (company) — Financial Instrument
- klrs:TwentyTwentyFiveBridgeNotesMember (company) — Financial Instrument
FAQ
What was Kalaris Therapeutics' revenue for the first quarter of 2025?
Kalaris Therapeutics reported $4.96 million in revenue for the first quarter of 2025.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
What are some of the key financial instruments mentioned in the filing?
Key financial instruments mentioned include klrs:SeriesBTwoRedeemableConvertiblePreferredStockMember and klrs:TwentyTwentyFiveBridgeNotesMember.
What was the diluted earnings per share for the period ending March 31, 2025?
The diluted earnings per share for the period ending March 31, 2025, was $0.201601.
What was Kalaris Therapeutics' former company name?
Kalaris Therapeutics, Inc. was formerly known as Allovir, Inc. and ViraCyte, Inc.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Kalaris Therapeutics, Inc. (KLRS).